Cevian Capital disclosed a stake above 14 percent in Smith & Nephew in a late-July filing, extending the Swedish activist's campaign against the London-listed medical device company. The position, now worth approximately $2.1 billion at current trading levels, represents Cevian's largest active European holding and marks the third disclosed stake increase since the firm's initial 5.1 percent position in September 2023.
The filing arrives seven months after Smith & Nephew announced CEO Deepak Nath would step down following sustained underperformance in the company's orthopedics and sports medicine divisions. Nath's departure came after Cevian co-founder Christer Gardell joined the board in February, a sequence that activist watchers recognize as the standard Cevian playbook. The firm does not issue press releases or host investor days. It takes board seats, installs executives, and waits.
Smith & Nephew shares trade at $24.12 in ADR form, down 11 percent year-to-date and roughly 28 percent below the five-year high reached in early 2021. The company's orthopedics revenue declined 3.2 percent in the most recent quarter, pressured by market share losses to Stryker and Zimmer Biomet in knee reconstruction. The sports medicine segment, once a growth engine, posted flat revenue as the company struggled to compete with Arthrex in the arthroscopy equipment market. Cevian's thesis centers on operational tightening and portfolio rationalization, the same framework it used at Volvo and Ericsson.
The 14 percent threshold matters because it positions Cevian to block certain special resolutions under UK takeover rules, though the firm has historically preferred operational transformation to sale processes. Worth noting: Smith & Nephew's wound management division, which generates roughly $2.4 billion in annual revenue, has drawn interest from private equity firms including EQT Partners, though no formal process has been disclosed. Cevian's continued accumulation suggests the firm sees the board transition and portfolio review as multi-year efforts, not quarters.
Allocators should watch for the new CEO announcement, expected before the October earnings call, and any disclosed conversations between Cevian and Smith & Nephew's remaining independent directors regarding the wound management carve-out. The firm's pattern at Ericsson—18 months from initial stake to operational restructuring—offers a rough timeline. Portfolio managers holding European healthcare exposure have begun trimming Smith & Nephew on the view that Cevian's involvement implies a 24-to-36-month value realization period, not a quick activist pop.
The next material event is the September board meeting, where the CEO search committee is scheduled to present final candidates. Cevian does not leak. It positions, waits, and extracts. The 14 percent filing is not escalation. It is confirmation that the firm sees the current share price as too cheap for what the business will look like in 2026.